SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is capturing significant attention due to its upcoming $1 million mainnet perpetuals trading competition and the launch of its V3 perps with multi-collateral support on Ethereum. The community is buzzing about the end of SNX token inflation and the start of buybacks, fueling bullish price speculation and increased trading volume.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is trending after the SEC dismissed its lawsuit and a significant partnership with AT&T emerged, solidifying its role in the DePIN sector. Community sentiment is highly polarized, with strong bullish conviction in its real-world utility and institutional interest contrasting with concerns over project management and token economics for miners.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is trending due to recent integrations with the COTI Network and AR.IO, ongoing "Glacier Drop" airdrop excitement, and mentions of major exchange listings, positioning it as a privacy-focused blockchain within the Cardano ecosystem for institutional adoption. The community is actively debating its growth potential and regulatory compliance compared to other privacy coins, while also discussing its relationship with ADA and associated meme coins like COCK.

WorldFinancial

WLFI is trending as an upcoming Mar-a-Lago forum, hosted by Trump's sons and featuring notable finance leaders, fuels intense community debate over potential institutional adoption against skepticism and an ongoing US House investigation into foreign investment ties.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is surging after securing FDA approval for BYSANTI with unexpected New Chemical Entity status, providing robust patent protection until 2044, which the community hails as a "Gold Standard" and a significant re-rating event that could attract big pharma. Discussion is focused on this long-term revenue moat and the "mega blockbuster" potential of its Tradipitant for GLP-1 nausea.

KeyCorp is a bank holding company, which engages in the provision of financial services. It operates through the Consumer Bank and Commercial Bank segments. The Consumer Bank segment offers deposit and investment products, personal finance and financial wellness services, lending, mortgage and home equity, student loan refinancing, credit card, treasury services, and business advisory services. The Commercial Bank segment focuses on serving the needs of middle market clients in seven industry sectors, consumer, energy, healthcare, industrial, public sector, real estate, and technology. The company was founded on December 31, 1958 and is headquartered in Cleveland, OH.

Keycorp

KeyCorp is trending as First Citizens BancShares is reportedly exploring a potential acquisition to quickly surpass $250 billion in assets, driving community discussion around the possibility of a takeout and its implications for share repricing. This news comes amidst ongoing chatter about KeyCorp's mixed momentum indicators despite recent revenue growth and strategic restructuring efforts.

Exchange Traded Concepts Trust - ROBO Global Robotics and Automation Index ETF

Exchange Traded Concepts Trust - ETCT ROBO Global Robotics and Automation Index ETF

The ROBO ETF is trending as the community widely anticipates a "physical AI revolution" and the "rise of the machine era," viewing it as a durable, long-term investment in automation poised for significant growth.

Lithium Argentina AG is a resource and materials company that engages in the production of lithium carbonate for lithium-ion batteries and electric vehicles. Its projects include: Cauchari-Olaroz and Pastos Grandes. The company was founded by Raymond Edward Flood, Jr. on November 27, 2007 and is headquartered in Zug, Switzerland.

Lithium Argentina AG

Lithium Argentina AG (LAR) is trending as rapidly rising lithium prices, fueled by recent supply reductions and increasing demand for EV and AI battery storage, position it for strong earnings. The community is actively discussing LAR's advantage as an in-production miner, anticipating a significant re-evaluation of its stock compared to peers.

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.

MeiraGTx Holdings plc

MeiraGTx Holdings is garnering significant attention due to its new ophthalmology gene therapy partnership with Eli Lilly and highly positive clinical data for its Parkinson's program, amplifying community belief in the stock's deep undervaluation given its robust pipeline and strategic collaborations with major pharmaceutical companies.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG) is trending as its community celebrates a significant one-year milestone, highlighting the token's resilience and its unique protocol that consistently distributes passive Solana rewards to holders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexeo Therapeutics (NASDAQ:LXEO) COO Jose Manuel Otero Sells 3,016 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) COO Jose Manuel Otero sold 3,016 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold...

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 10,173 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 10,173 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The shares...

Jose Manuel Otero Sells 3,016 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) COO Jose Manuel Otero sold 3,016 shares of Lexeo Therapeutics stock in a transaction on Wednesday, February 18th. The shares were sold at an...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One...

Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit

Executives from Lexeo Therapeutics (NASDAQ:LXEO) outlined regulatory plans, clinical data, and manufacturing updates for its lead gene therapy programs during a presentation at Guggenheim's 2026...

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2% - Time to Sell?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 3.2% - Should You Sell...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst...

Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Rises By 52.5%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 10,830,747 shares, a...

Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down - Here's What Happened

Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down - What's Next...

Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9% - Still a Buy?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9% - Here's Why...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXEO News

LXEOLexeo Therapeutics Inc.